Dr Valentin Goede: New anti CD-20 agent for the treatment of CLL MD-FM The first medical webradio Currently, the anti-CD-20 monoclonal antibody rituximab is a standard of care for these patients. A second anti-CD-20 antibody, ofatumumab came out in 2012, and now a third one, obinutuzumab, at the end of last year. Trials are currently ongoing to ... |
